Skip to main content

Advertisement

SpringerLink
Log in

The development of parathyroid hormone as anabolic therapy for osteoporosis

A timeline

  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

At first glance, parathyroid hormone (PTH) peptides seem rather unlikely candidates as treatments for osteoporosis. For the better part of the last century, we focused almost exclusively on the catabolic action of these peptides on bone, despite the fact that anabolic activity had been demonstrated as early as 1929. The intent of this article is to provide snapshots, of the key events that occurred during the ensuing 74 yr that led to the development of PTH peptides as approved treatments for osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Potts JT, Jr 2005 Parathyroid hormone: past and present. J. Endocrinol 187:311–325.

    CAS  PubMed  Google Scholar 

  2. Owen R 1862 On the anatomy of the Indian rhinoceros (Rh. Unicornis). Trans Zool Soc Lond 4:31–58.

    Google Scholar 

  3. Sandstrom I. 1880 Om en ny kortel hosmenniskan och atskilliga daggdjur. Uppsala Lakaref Forhande 15:441–71.

    Google Scholar 

  4. Aidan Carney, J. 1996 The Glandulae Parathyroideae of Ivar Sandström: contributions from two continents. Am J Surg Pathol 20:1123–1144.

    Google Scholar 

  5. Erdheim J. 1904 Beitrage zur pathologischen anatomie der menschlichen epithelkorperchen. Zeitschr f heik 25:1–15.

    Google Scholar 

  6. Erdheim J. 1906 Ueber tetania parathyreopreva. Wien Klin Wehnschr 716–717.

  7. Mandl F. 1926 Therapeutischer Versuch bein einem Fall von Ostitis fibrosa generalisata mittles. Exstirpation eines Epithelkorperchentumors. Wien Klin Wochenschr Zentral 53:260–64.

    Google Scholar 

  8. Mandl, F. 1957 Surgery of the thyroid and parathyroids: diseases of the parathyroids. J Int Coll Surg 27:520–527.

    CAS  PubMed  Google Scholar 

  9. Collip JB. 1925 The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 63:395–438.

    CAS  Google Scholar 

  10. Li A. 1992 J.B. Collip and A.M. Hanson and the Isolation of the Parathyroid Hormone, or Endocrines and Enterprise. J Hist Med Allied Sci 47:405–438.

    CAS  PubMed  Google Scholar 

  11. Bauer W, Aub JC, Albright F. 1929 Studies of calcium phosphorus metabolism: V. A. study of the bone trabeculae as a readily available reserve supply of calcium. J. Exp Med 49:145–162.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Bülbring E. 1931 Über die Beziehungen zwischen Epithelkörperchen, Calciumstoffwechsel und Knochenwachstum. Arch Exp Path u Pharm 162:209–248.

    Google Scholar 

  13. Selye H. 1932 On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 16:547–558.

    CAS  Google Scholar 

  14. Burrows R. 1938 Variations produced in bones of growing rats by parathyroid extracts. Am J Anat 62:237–290.

    CAS  Google Scholar 

  15. Barnicot NA. 1948 The local action of the parathyroid and other tissues on bone in intracerebral grafts. J Anat (London) 82:233–248.

    Google Scholar 

  16. Aurbach GD. 1959 Isolation of parathyroid hormone after extraction with phenol. J Biolog Chem 234:3179–3181.

    CAS  Google Scholar 

  17. Rasmussen H, Craig LC. 1959 Purification of parathyroid hormone by use of counter-current distribution. J Am Chem Soc 81:5003.

    CAS  Google Scholar 

  18. Brewer HB Jr, Ronan R. 1970 Bovine parathyroid hormone: amino acid sequence. Proc Nalt Acad Sci U S A 67: 1862–1869.

    CAS  Google Scholar 

  19. Niall HD, Keutmann HT, Sauer RT, Hogan M, et al. 1970 The amino acid sequence of bovine parathyroid hormone I. Hoppe-Seyler's Zeitschrift für Physiologische Chemie 351:1586–1588.

    CAS  PubMed  Google Scholar 

  20. Kalu DN, Pennock J, Doyle FH, Foster, GV. 1970 Parathyroid hormone and experimental osteosclerosis. Lancet i:1363–1366.

    Google Scholar 

  21. Potts JT Jr, Tregear GW, Keutmann HT, et al. 1971 Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone. Proc Natl Acad Sci U S A 68:63–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Brewer HB Jr, Fairwell T, Ronan R, Sizemore GW, Arnaud CD, 1972 Human parathyroid hormone: amino-acid sequence of the amino-terminal residues 1-34. Proc Natl Acad Sci U S A 69:3585–3588.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Niall HD, Sauer RT, Jacobs JW, et al. 1974 The amino acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A 71:384–388.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Reeve J, Veall N. 1972 Radioisotope studies of calcium metabolism and their interpretation. Clin Endocrinol Metab 1:185–196.

    Google Scholar 

  25. Tregear GW, van Rietschoten J, et al. 1974. Solid-phase synthesis of the biologically active N-terminal 1-34 peptide of human parathyroid hormone. Hoppe-Seyler's Z Physiol Chem 355:415–421.

    CAS  Google Scholar 

  26. Reeve J, Hesp R, Williams D, et al. 1976. The anabolic effect of low doses of human parathyroid hormone fragment on the skeleton in postmenopausal osteoporosis. Lancet 1:1035–1038.

    CAS  PubMed  Google Scholar 

  27. Reeve J, Meunier PJ, Parsons JA et al 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280:1340–1344.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Tam CS, Heersche JN, Murray TM, Parsons JA. 1982 Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506–512

    CAS  PubMed  Google Scholar 

  29. Podbesek R, Edouard C, Meunier PJ, et al. 1983. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhouds. Endocrinology 112:1000–1006.

    CAS  PubMed  Google Scholar 

  30. Reeve J, Bradbeer JN, Arlot M, et al. 1991. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1;162–170.

    CAS  PubMed  Google Scholar 

  31. Hodsman AB, Fraher LJ, Watson PH, et al. 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82(2):620–628.

    CAS  PubMed  Google Scholar 

  32. Hodsman AB, Steer BM. 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523–527.

    CAS  PubMed  Google Scholar 

  33. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM. 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138–1148.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Slovik DM, Rosenthal DI, Doppelt SH, et al. 1986 Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1:377–381.

    CAS  PubMed  Google Scholar 

  35. Lindsay R, Nieves J, Formica C, et al. 1997 Randomised controlled study of effect of parathyroid hormone on vertebralbone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350(9077): 550–555.

    CAS  PubMed  Google Scholar 

  36. Lane NE, Sanchez S, Modin GW, et al. 1998 Parathyroid hormone can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial J Clin Invest 102:1627–1633.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Rittmaster RS, Bolognese M, Ettinger MP, et al. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85(6):2129–2134.

    CAS  PubMed  Google Scholar 

  38. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001 Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 344:1434–1441.

    CAS  Google Scholar 

  39. Dempster DW, Cosman F, Kurland ES, et al. 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853.

    CAS  PubMed  Google Scholar 

  40. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941.

    CAS  PubMed  Google Scholar 

  41. Hodsman AB, Hanley DA, Ettinger MP, et al. 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220.

    CAS  PubMed  Google Scholar 

  42. Orwoll ES, Scheele WH, Paul S, et al 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17.

    CAS  PubMed  Google Scholar 

  43. Black DM, Greenspan SL, Ensrud KE, et al., and; PaTH Study Investigators. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215.

    CAS  PubMed  Google Scholar 

  44. Ettinger B, San Martin J, Crans G, Pavo I. 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751.

    CAS  PubMed  Google Scholar 

  45. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15:992–997.

    CAS  PubMed  Google Scholar 

  46. Black DM, Bilezikian JP, Ensrud KE, et al., and PaTH Study Investigators. 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Eng J Med 353:555–565.

    CAS  Google Scholar 

  47. Deal C, Omizo M, Schwartz EN, et al. 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebocontrolled trial. J Bone Miner Res 20:1905–1911.

    CAS  PubMed  Google Scholar 

  48. Greenspan S, Bone H, Marriott T, eet al. 2005 Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study. J Bone Miner Res 1222:S56

    Google Scholar 

  49. Miller PD, Greenspan S, PTH(1-84) prevents vertebral fracture in postmenopausal women with higher fracture risk: Results from the TOP study. Osteoporos Int 16(S4):S32

  50. Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA. 2006 Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21:283–291

    CAS  PubMed  Google Scholar 

  51. McClung MR, San Martin J, Miller PD, et al. 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768

    CAS  PubMed  Google Scholar 

  52. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566–575

    CAS  PubMed  Google Scholar 

  53. Lindsay R, Cosman F, Zhou H, et al. 2006 A novel tetracycline labeling schedule for longitudinal, evaluation of the short-erm effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366–373.

    CAS  PubMed  Google Scholar 

  54. Dobnig H, Sipos A, Jiang Y, et al. 2005. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977.

    CAS  PubMed  Google Scholar 

  55. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. 2006 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61–66.

    CAS  PubMed  Google Scholar 

  56. Bauer DC, Garnero P, Bilezikian JP et al. 2006 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370–1375.

    CAS  PubMed  Google Scholar 

  57. Tashjian AH Jr, Gagel RF. 2006 Teriparatide [human PTH(1-34)]: 2.5 years of experience of the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354–365.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, College of Physicians and Surgeons of Columbia University, New York

    David W. Dempster PhD

  2. University Department of Medicine, Addenbrooke's Hospital, Cambridge, UK

    Jonathan Reeve

  3. Regional Bone Center, Helen Hayes Hospital, 10993, West Haverstraw, NY

    David W. Dempster PhD

Authors
  1. David W. Dempster PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Reeve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David W. Dempster PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dempster, D.W., Reeve, J. The development of parathyroid hormone as anabolic therapy for osteoporosis. Clinic Rev Bone Miner Metab 4, 227–231 (2006). https://doi.org/10.1385/BMM:4:4:227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1385/BMM:4:4:227

Key Words

Search

Navigation